Original BioMedicals Co., Ltd.
Original BioMedicals Co., Ltd., engages in the development of new drugs with non-new ingredients in Taiwan. It develops OBM-A01, for the treatment of acute radiation injury, including nuclear radiation and solar radiation exposed in space; OBM-B01, a cyanide compound drug for protection against toxic gases from fires; and CCM-CL, a cyclic polypeptide antibiotic. The company was founded in 2011 an… Read more
Original BioMedicals Co., Ltd. (6483) - Total Assets
Latest total assets as of June 2025: NT$233.55 Million TWD
Based on the latest financial reports, Original BioMedicals Co., Ltd. (6483) holds total assets worth NT$233.55 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Original BioMedicals Co., Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how Original BioMedicals Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Original BioMedicals Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Original BioMedicals Co., Ltd.'s total assets of NT$233.55 Million consist of 91.7% current assets and 8.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 54.2% |
| Accounts Receivable | NT$697.00K | 0.3% |
| Inventory | NT$0.00 | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Original BioMedicals Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Original BioMedicals Co., Ltd.'s current assets represent 91.7% of total assets in 2024, an increase from 34.7% in 2019.
- Cash Position: Cash and equivalents constituted 54.2% of total assets in 2024, up from 24.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
Original BioMedicals Co., Ltd. Competitors by Total Assets
Key competitors of Original BioMedicals Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Original BioMedicals Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Original BioMedicals Co., Ltd. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Original BioMedicals Co., Ltd. is currently not profitable relative to its asset base.
Original BioMedicals Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.55 | 24.53 | 3.57 |
| Quick Ratio | 13.55 | 24.53 | 3.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$198.56 Million | NT$ 284.06 Million | NT$ 18.12 Million |
Original BioMedicals Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between Original BioMedicals Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.37 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -24.6% |
| Total Assets | NT$279.37 Million |
| Market Capitalization | $26.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Original BioMedicals Co., Ltd.'s assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Original BioMedicals Co., Ltd.'s assets decreased by 24.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Original BioMedicals Co., Ltd. (2019–2024)
The table below shows the annual total assets of Original BioMedicals Co., Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$279.37 Million | -24.62% |
| 2023-12-31 | NT$370.63 Million | +278.05% |
| 2022-12-31 | NT$98.04 Million | -28.63% |
| 2021-12-31 | NT$137.37 Million | +103.80% |
| 2020-12-31 | NT$67.40 Million | -28.19% |
| 2019-12-31 | NT$93.86 Million | -- |